KR20100027102A - 마이크로ｒｎａ를 이용한 암환자의 치료 후 생존을 예측하는 방법 - Google Patents

마이크로ｒｎａ를 이용한 암환자의 치료 후 생존을 예측하는 방법 Download PDF

Info

Publication number
KR20100027102A
KR20100027102A KR1020097023492A KR20097023492A KR20100027102A KR 20100027102 A KR20100027102 A KR 20100027102A KR 1020097023492 A KR1020097023492 A KR 1020097023492A KR 20097023492 A KR20097023492 A KR 20097023492A KR 20100027102 A KR20100027102 A KR 20100027102A
Authority
KR
South Korea
Prior art keywords
hsa
expression
patient
survival
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097023492A
Other languages
English (en)
Korean (ko)
Inventor
지안-웨이 첸
성-리앙 위
수안-위 첸
지-첸 장
치-이 첸
팬-치르 양
Original Assignee
내셔널 타이완 유니버시티
디씨비-유에스에이 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 내셔널 타이완 유니버시티, 디씨비-유에스에이 엘엘씨 filed Critical 내셔널 타이완 유니버시티
Publication of KR20100027102A publication Critical patent/KR20100027102A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020097023492A 2007-04-10 2008-04-09 마이크로ｒｎａ를 이용한 암환자의 치료 후 생존을 예측하는 방법 Withdrawn KR20100027102A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91099307P 2007-04-10 2007-04-10
US60/910,993 2007-04-10

Publications (1)

Publication Number Publication Date
KR20100027102A true KR20100027102A (ko) 2010-03-10

Family

ID=39831416

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097023492A Withdrawn KR20100027102A (ko) 2007-04-10 2008-04-09 마이크로ｒｎａ를 이용한 암환자의 치료 후 생존을 예측하는 방법

Country Status (13)

Country Link
US (1) US7745134B2 (enExample)
EP (1) EP2134874A4 (enExample)
JP (1) JP2010523156A (enExample)
KR (1) KR20100027102A (enExample)
CN (1) CN101688240A (enExample)
AU (1) AU2008237036A1 (enExample)
CA (1) CA2695868A1 (enExample)
CO (1) CO6231056A2 (enExample)
IL (1) IL201298A0 (enExample)
MX (1) MX2009010899A (enExample)
RU (1) RU2009141359A (enExample)
TW (1) TWI367949B (enExample)
WO (1) WO2008124777A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103866018B (zh) 2005-08-01 2016-05-25 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
CN103028120B (zh) 2005-09-12 2015-08-12 俄亥俄州立大学研究基金会 用于诊断或治疗bcl2相关癌症的组合物和方法
WO2007081720A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
ES2524018T3 (es) 2006-01-05 2014-12-03 The Ohio State University Research Foundation Anomalías de la expresión de microARN en tumores pancreáticos endocrinos y acinares
EP2487260B1 (en) 2006-01-05 2015-07-08 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis and treatment of solid cancers
EP2369012A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Micro-RNA fingerprints during human megakaryocytopoiesis
CA2657030A1 (en) 2006-07-13 2008-01-17 The Ohio State University Research Foundation, An Instrumentality Of The State Of Ohio Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
US8071292B2 (en) 2006-09-19 2011-12-06 The Ohio State University Research Foundation Leukemia diagnostic methods
JP5501766B2 (ja) 2006-11-01 2014-05-28 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 肝細胞癌における生存および転移を予測するためのマイクロｒｎａ発現サイン
US8034560B2 (en) 2007-01-31 2011-10-11 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (AML)
CA2690144A1 (en) * 2007-06-08 2008-12-18 The Government Of The United States Of America As Represented By The Sec Retary Of Department Of Health And Human Services Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells
US8053186B2 (en) 2007-06-15 2011-11-08 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
ES2496172T3 (es) 2007-07-31 2014-09-18 The Ohio State University Research Foundation Métodos para invertir la metilación por selección dirigida de DNMT3A y DNMT3B
AU2008283997B2 (en) 2007-08-03 2014-04-10 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
CN101836112A (zh) 2007-08-22 2010-09-15 俄亥俄州立大学研究基金会 用于在人急性白血病中诱导epha7和erk磷酸化的脱调节的方法和组合物
CA2703707A1 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
AU2009257410B2 (en) 2008-06-11 2014-03-06 Fudan University Use of miR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
WO2010054386A2 (en) * 2008-11-10 2010-05-14 Battelle Memorial Institute Methods, compositions, and devices utilizing microrna to determine physiological conditions
US8729041B2 (en) 2008-12-03 2014-05-20 The Johns Hopkins University Compositions and methods for treating hepatic neoplasia
EP2196543A1 (en) * 2008-12-15 2010-06-16 Koninklijke Philips Electronics N.V. Compositions and methods for micro-rna expression profiling of hepatocellular cancer
WO2010094155A1 (en) * 2009-02-23 2010-08-26 Capitalbio Corporation Methods and compositions diagnosing lung cancer, determining prognosis, and improving patient survival
CN101638656B (zh) * 2009-08-28 2011-05-11 南京医科大学 一种与非小细胞肺癌预后相关的血清/血浆miRNA标志物及其应用
JP5960060B2 (ja) 2009-11-23 2016-08-02 ジ・オハイオ・ステート・ユニバーシティ 腫瘍細胞の増殖、遊走および浸潤に影響を与えるために有用な物質および方法
JP5763098B2 (ja) * 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
US20110223607A1 (en) 2010-03-12 2011-09-15 Quest Diagnostics Investments Incorporated Circulating microrna as a marker for hepatocellular carcinoma
WO2012065049A1 (en) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
CA2817982C (en) 2010-11-15 2020-06-30 The Regents Of The University Of Michigan Controlled release mucoadhesive systems
US8664192B2 (en) 2011-03-07 2014-03-04 The Ohio State University Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
US8404437B2 (en) 2011-03-29 2013-03-26 Taipei Veterans General Hospital MicroRNA as a cancer progression predictor and its use for treating cancer
US20140113978A1 (en) * 2011-05-01 2014-04-24 University Of Rochester Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof
EP2757154A4 (en) 2011-09-16 2015-10-14 Lsip Llc METHOD FOR DETECTING BLOOD TUMOR CELLS, PRIMER FOR USE IN THIS METHOD FOR DETECTING BLOOD TUMOR CELLS AND BLADDER CANCER MARKERS
EP2766500A4 (en) 2011-10-14 2015-10-14 Univ Ohio State METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER
CN104619353A (zh) 2011-12-13 2015-05-13 俄亥俄州国家创新基金会 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移
US9850541B2 (en) * 2011-12-19 2017-12-26 Valley Health System Methods and kits for detecting subjects at risk of having cancer
JP2015511121A (ja) 2012-01-20 2015-04-16 ジ・オハイオ・ステート・ユニバーシティ 浸潤性および予後に関する乳がんバイオマーカーシグネチャー
US8846316B2 (en) 2012-04-30 2014-09-30 Industrial Technology Research Institute Biomarker for human liver cancer
US10738363B2 (en) 2016-08-31 2020-08-11 National Central University Analyzer and analytical method for predicting prognosis of cancer radiotherapy
DE102018110526A1 (de) 2018-05-02 2019-11-07 Faurecia Autositze Gmbh Verfahren zur Montage eines Linearaktuators für einen Kraftfahrzeugsitz
CN108630317B (zh) * 2018-05-09 2022-04-15 中国科学院昆明动物研究所 一种基于多基因表达特征谱的肝癌个性化预后评估方法
CN108320806B (zh) * 2018-05-09 2022-04-12 中国科学院昆明动物研究所 一种基于多基因表达特征谱的结肠癌个性化预后评估方法
CN108647493B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 一种肾透明细胞癌个性化预后评估方法
CN108470111B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 一种基于多基因表达特征谱的胃癌个性化预后评估方法
CN108611416B (zh) * 2018-05-09 2020-12-29 中国科学院昆明动物研究所 一种基于多基因表达特征谱的宫颈癌个性化预后评估方法
CN108733980B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 基于多基因表达特征谱胶质母细胞瘤个性化预后评估方法
CN108648826B (zh) * 2018-05-09 2022-04-15 中国科学院昆明动物研究所 一种基于多基因表达特征谱的胰腺癌个性化预后评估方法
CN108363907B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 一种基于多基因表达特征谱的肺腺癌个性化预后评估方法
US11410745B2 (en) * 2018-06-18 2022-08-09 International Business Machines Corporation Determining potential cancer therapeutic targets by joint modeling of survival events
TWI758670B (zh) * 2018-12-24 2022-03-21 奎克生技光電股份有限公司 健康風險評估方法
CN111172285A (zh) * 2020-02-26 2020-05-19 江南大学附属医院 用于胰腺癌早期诊断和/或预后监测的miRNA组及其应用
TWI878107B (zh) * 2024-04-30 2025-03-21 朱旆億 乳癌預後存活率預測模型建立方法及系統

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029287A2 (en) * 2002-09-27 2004-04-08 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer
US20040152112A1 (en) * 2002-11-13 2004-08-05 Thomas Jefferson University Compositions and methods for cancer diagnosis and therapy
CA2554818A1 (en) * 2004-02-09 2005-08-25 Thomas Jefferson University Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
US20050272067A1 (en) * 2004-03-10 2005-12-08 Macina Roberto A Compositions, splice variants and methods relating to cancer specific genes and proteins
US20060078913A1 (en) * 2004-07-16 2006-04-13 Macina Roberto A Compositions, splice variants and methods relating to cancer specific genes and proteins
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling

Also Published As

Publication number Publication date
US20080254473A1 (en) 2008-10-16
US7745134B2 (en) 2010-06-29
AU2008237036A2 (en) 2010-09-09
WO2008124777A1 (en) 2008-10-16
CN101688240A (zh) 2010-03-31
IL201298A0 (en) 2010-05-31
AU2008237036A1 (en) 2008-10-16
EP2134874A1 (en) 2009-12-23
TWI367949B (en) 2012-07-11
EP2134874A4 (en) 2010-12-22
TW200912002A (en) 2009-03-16
RU2009141359A (ru) 2011-05-20
MX2009010899A (es) 2010-02-17
JP2010523156A (ja) 2010-07-15
CO6231056A2 (es) 2010-12-20
CA2695868A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
KR20100027102A (ko) 마이크로ｒｎａ를 이용한 암환자의 치료 후 생존을 예측하는 방법
Zhou et al. Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer
Spahn et al. Expression of microRNA‐221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence
Feber et al. MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma
Childs et al. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma
Nadal et al. A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma
Hoppe et al. Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment
Ichinose et al. Alternative polyadenylation is associated with lower expression of PABPN 1 and poor prognosis in non‐small cell lung cancer
Li et al. Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma
Rahbari et al. Identification of differentially expressed microRNA in parathyroid tumors
Han et al. miRNAs as biomarkers and for the early detection of non-small cell lung cancer (NSCLC)
Bagnoli et al. Identification of a chrXq27. 3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients
Zhang et al. Down-regulation of long non-coding RNA MEG3 serves as an unfavorable risk factor for survival of patients with breast cancer
CN103243161B (zh) 一种辅助预测食管鳞癌患者术后生存时间长短的产品
Chen et al. MiRNA expression profile reveals a prognostic signature for esophageal squamous cell carcinoma
Cheng et al. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients
Papaioannou et al. Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia
AU2009246009A1 (en) Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
WO2021036620A1 (zh) 一组卵巢癌预后相关基因的应用
Hu et al. Genetic polymorphisms in the precursor microrna flanking region and non–small cell lung cancer survival
JP2017521058A (ja) 癌処置のための個別化三剤治療を選択するための方法
CN113444804B (zh) 宫颈癌预后相关基因及其在制备宫颈癌预后预测诊断产品中的应用
Sun et al. Screening of differently expressed miRNA and mRNA in prostate cancer by integrated analysis of transcription data
Chen et al. Circulating miR-148b-3p and miR-409-3p as biomarkers for heart failure in patients with mitral regurgitation
Sun et al. Prognostic implications of novel gene signatures in gastric cancer microenvironment

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20091110

Patent event code: PA01051R01D

Comment text: International Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20100125

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid